In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Immatics (IMTX), with a price target of $30.00. The company’s shares closed last Wednesday at $15.19.

According to, Livshits is a top 100 analyst with an average return of 81.9% and a 75.2% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immatics with a $28.00 average price target, an 80.6% upside from current levels. In a report released today, Leerink Partners also maintained a Buy rating on the stock with a $26.00 price target.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company’s pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.

Source link